|
Gene: DHX36 |
Gene summary for DHX36 |
Gene summary. |
Gene information | Species | Human | Gene symbol | DHX36 | Gene ID | 170506 |
Gene name | DEAH-box helicase 36 | |
Gene Alias | DDX36 | |
Cytomap | 3q25.2 | |
Gene Type | protein-coding | GO ID | GO:0000003 | UniProtAcc | Q9H2U1 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
170506 | DHX36 | CA_HPV_1 | Human | Cervix | CC | 4.89e-06 | -9.12e-02 | 0.0264 |
170506 | DHX36 | CCI_2 | Human | Cervix | CC | 2.02e-10 | 9.69e-01 | 0.5249 |
170506 | DHX36 | CCI_3 | Human | Cervix | CC | 4.22e-03 | 5.61e-01 | 0.516 |
170506 | DHX36 | L1 | Human | Cervix | CC | 3.61e-02 | -2.59e-01 | 0.0802 |
170506 | DHX36 | LZE2T | Human | Esophagus | ESCC | 1.71e-11 | 1.54e+00 | 0.082 |
170506 | DHX36 | LZE3D | Human | Esophagus | HGIN | 1.07e-02 | 3.13e-01 | 0.0668 |
170506 | DHX36 | LZE4T | Human | Esophagus | ESCC | 5.44e-29 | 9.90e-01 | 0.0811 |
170506 | DHX36 | LZE5T | Human | Esophagus | ESCC | 1.18e-03 | 4.36e-01 | 0.0514 |
170506 | DHX36 | LZE7T | Human | Esophagus | ESCC | 1.26e-13 | 9.67e-01 | 0.0667 |
170506 | DHX36 | LZE8T | Human | Esophagus | ESCC | 3.23e-14 | 3.61e-01 | 0.067 |
170506 | DHX36 | LZE22T | Human | Esophagus | ESCC | 1.82e-05 | 4.13e-01 | 0.068 |
170506 | DHX36 | LZE24T | Human | Esophagus | ESCC | 8.51e-30 | 9.52e-01 | 0.0596 |
170506 | DHX36 | LZE22D3 | Human | Esophagus | HGIN | 4.37e-02 | 3.42e-01 | 0.0653 |
170506 | DHX36 | LZE21T | Human | Esophagus | ESCC | 1.77e-15 | 1.24e+00 | 0.0655 |
170506 | DHX36 | P1T-E | Human | Esophagus | ESCC | 4.39e-25 | 1.28e+00 | 0.0875 |
170506 | DHX36 | P2T-E | Human | Esophagus | ESCC | 3.41e-107 | 2.18e+00 | 0.1177 |
170506 | DHX36 | P4T-E | Human | Esophagus | ESCC | 1.12e-56 | 1.60e+00 | 0.1323 |
170506 | DHX36 | P5T-E | Human | Esophagus | ESCC | 4.49e-55 | 1.01e+00 | 0.1327 |
170506 | DHX36 | P8T-E | Human | Esophagus | ESCC | 9.12e-79 | 1.35e+00 | 0.0889 |
170506 | DHX36 | P9T-E | Human | Esophagus | ESCC | 6.51e-51 | 1.26e+00 | 0.1131 |
Page: 1 2 3 4 5 6 7 8 9 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:000218110 | Cervix | CC | cytoplasmic translation | 96/2311 | 148/18723 | 4.87e-51 | 2.91e-47 | 96 |
GO:002260410 | Cervix | CC | regulation of cell morphogenesis | 84/2311 | 309/18723 | 1.00e-12 | 4.29e-10 | 84 |
GO:000989610 | Cervix | CC | positive regulation of catabolic process | 109/2311 | 492/18723 | 5.26e-10 | 6.99e-08 | 109 |
GO:003133110 | Cervix | CC | positive regulation of cellular catabolic process | 91/2311 | 427/18723 | 9.64e-08 | 5.25e-06 | 91 |
GO:003133010 | Cervix | CC | negative regulation of cellular catabolic process | 63/2311 | 262/18723 | 1.10e-07 | 5.68e-06 | 63 |
GO:00107699 | Cervix | CC | regulation of cell morphogenesis involved in differentiation | 31/2311 | 96/18723 | 2.43e-07 | 1.05e-05 | 31 |
GO:00163587 | Cervix | CC | dendrite development | 58/2311 | 243/18723 | 4.52e-07 | 1.76e-05 | 58 |
GO:00064029 | Cervix | CC | mRNA catabolic process | 56/2311 | 232/18723 | 4.81e-07 | 1.83e-05 | 56 |
GO:00018197 | Cervix | CC | positive regulation of cytokine production | 95/2311 | 467/18723 | 4.88e-07 | 1.85e-05 | 95 |
GO:19001517 | Cervix | CC | regulation of nuclear-transcribed mRNA catabolic process, deadenylation-dependent decay | 11/2311 | 18/18723 | 1.37e-06 | 4.55e-05 | 11 |
GO:19033119 | Cervix | CC | regulation of mRNA metabolic process | 64/2311 | 288/18723 | 1.71e-06 | 5.64e-05 | 64 |
GO:000989510 | Cervix | CC | negative regulation of catabolic process | 69/2311 | 320/18723 | 2.15e-06 | 6.55e-05 | 69 |
GO:00064019 | Cervix | CC | RNA catabolic process | 62/2311 | 278/18723 | 2.18e-06 | 6.56e-05 | 62 |
GO:00109757 | Cervix | CC | regulation of neuron projection development | 88/2311 | 445/18723 | 4.26e-06 | 1.09e-04 | 88 |
GO:00107206 | Cervix | CC | positive regulation of cell development | 64/2311 | 298/18723 | 5.69e-06 | 1.41e-04 | 64 |
GO:00712148 | Cervix | CC | cellular response to abiotic stimulus | 69/2311 | 331/18723 | 7.36e-06 | 1.73e-04 | 69 |
GO:01040048 | Cervix | CC | cellular response to environmental stimulus | 69/2311 | 331/18723 | 7.36e-06 | 1.73e-04 | 69 |
GO:00313467 | Cervix | CC | positive regulation of cell projection organization | 72/2311 | 353/18723 | 1.04e-05 | 2.32e-04 | 72 |
GO:003425010 | Cervix | CC | positive regulation of cellular amide metabolic process | 40/2311 | 162/18723 | 1.11e-05 | 2.41e-04 | 40 |
GO:00609965 | Cervix | CC | dendritic spine development | 28/2311 | 99/18723 | 1.61e-05 | 3.15e-04 | 28 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0301824 | Esophagus | ESCC | RNA degradation | 62/4205 | 79/8465 | 1.18e-07 | 9.39e-07 | 4.81e-07 | 62 |
hsa0301834 | Esophagus | ESCC | RNA degradation | 62/4205 | 79/8465 | 1.18e-07 | 9.39e-07 | 4.81e-07 | 62 |
hsa03018 | Liver | Cirrhotic | RNA degradation | 44/2530 | 79/8465 | 1.43e-06 | 1.65e-05 | 1.02e-05 | 44 |
hsa030181 | Liver | Cirrhotic | RNA degradation | 44/2530 | 79/8465 | 1.43e-06 | 1.65e-05 | 1.02e-05 | 44 |
hsa030182 | Liver | HCC | RNA degradation | 58/4020 | 79/8465 | 2.29e-06 | 2.19e-05 | 1.22e-05 | 58 |
hsa030183 | Liver | HCC | RNA degradation | 58/4020 | 79/8465 | 2.29e-06 | 2.19e-05 | 1.22e-05 | 58 |
hsa030189 | Oral cavity | OSCC | RNA degradation | 59/3704 | 79/8465 | 2.05e-08 | 1.91e-07 | 9.70e-08 | 59 |
hsa0301814 | Oral cavity | OSCC | RNA degradation | 59/3704 | 79/8465 | 2.05e-08 | 1.91e-07 | 9.70e-08 | 59 |
hsa0301823 | Oral cavity | LP | RNA degradation | 39/2418 | 79/8465 | 6.98e-05 | 4.38e-04 | 2.83e-04 | 39 |
hsa0301833 | Oral cavity | LP | RNA degradation | 39/2418 | 79/8465 | 6.98e-05 | 4.38e-04 | 2.83e-04 | 39 |
hsa0301841 | Oral cavity | EOLP | RNA degradation | 22/1218 | 79/8465 | 1.33e-03 | 4.80e-03 | 2.83e-03 | 22 |
hsa0301851 | Oral cavity | EOLP | RNA degradation | 22/1218 | 79/8465 | 1.33e-03 | 4.80e-03 | 2.83e-03 | 22 |
hsa0301861 | Oral cavity | NEOLP | RNA degradation | 18/1112 | 79/8465 | 1.25e-02 | 4.06e-02 | 2.56e-02 | 18 |
hsa0301871 | Oral cavity | NEOLP | RNA degradation | 18/1112 | 79/8465 | 1.25e-02 | 4.06e-02 | 2.56e-02 | 18 |
hsa030188 | Prostate | BPH | RNA degradation | 29/1718 | 79/8465 | 5.17e-04 | 2.67e-03 | 1.65e-03 | 29 |
hsa0301813 | Prostate | BPH | RNA degradation | 29/1718 | 79/8465 | 5.17e-04 | 2.67e-03 | 1.65e-03 | 29 |
hsa0301822 | Prostate | Tumor | RNA degradation | 30/1791 | 79/8465 | 4.48e-04 | 2.35e-03 | 1.46e-03 | 30 |
hsa0301832 | Prostate | Tumor | RNA degradation | 30/1791 | 79/8465 | 4.48e-04 | 2.35e-03 | 1.46e-03 | 30 |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
DHX36 | SNV | Missense_Mutation | rs777610388 | c.626C>T | p.Ser209Leu | p.S209L | Q9H2U1 | protein_coding | deleterious(0) | possibly_damaging(0.51) | TCGA-B5-A0JY-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | SD |
DHX36 | SNV | Missense_Mutation | novel | c.1927N>G | p.Ile643Val | p.I643V | Q9H2U1 | protein_coding | tolerated(0.08) | possibly_damaging(0.574) | TCGA-B5-A11N-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
DHX36 | SNV | Missense_Mutation | novel | c.880A>T | p.Ile294Phe | p.I294F | Q9H2U1 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-B5-A1MX-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Hormone Therapy | megace | SD |
DHX36 | SNV | Missense_Mutation | novel | c.2081C>A | p.Ala694Glu | p.A694E | Q9H2U1 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-B5-A1N2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Chemotherapy | paclitaxel | PD |
DHX36 | SNV | Missense_Mutation | novel | c.287N>C | p.Val96Ala | p.V96A | Q9H2U1 | protein_coding | tolerated(0.71) | benign(0.001) | TCGA-B5-A3FA-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
DHX36 | SNV | Missense_Mutation | novel | c.2074C>A | p.His692Asn | p.H692N | Q9H2U1 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-B5-A3FC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
DHX36 | SNV | Missense_Mutation | rs754807929 | c.1690G>A | p.Val564Ile | p.V564I | Q9H2U1 | protein_coding | deleterious(0.03) | probably_damaging(0.954) | TCGA-B5-A3FC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
DHX36 | SNV | Missense_Mutation | novel | c.283A>C | p.Ile95Leu | p.I95L | Q9H2U1 | protein_coding | tolerated(0.08) | possibly_damaging(0.787) | TCGA-B5-A3FC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
DHX36 | SNV | Missense_Mutation | novel | c.2770N>A | p.Asp924Asn | p.D924N | Q9H2U1 | protein_coding | tolerated(0.31) | benign(0.009) | TCGA-BS-A0UV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
DHX36 | SNV | Missense_Mutation | c.2900N>C | p.Val967Ala | p.V967A | Q9H2U1 | protein_coding | deleterious(0.03) | benign(0.441) | TCGA-D1-A17H-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
170506 | DHX36 | NA | MANOALIDE | MANOALIDE | 22394195 |
Page: 1 |